# ST-01156

Source: https://onco.cc/drugs/st-01156/  
OnCo record `st-01156` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

ST-01156 is an experimental oral small-molecule molecular glue degrader from SEED Therapeutics, in phase 1 trials for ewing sarcoma, hepatocellular carcinoma and biliary tract cancer and other cancers.

## Summary

ST-01156 is an oral small-molecule molecular glue degrader from SEED Therapeutics. An orally given, brain-penetrant small-molecule degrader of RBM39 that brings RBM39 together with the E3 ligase DCAF15, designed to remove oncogenic RNA-splicing dependencies across tumour types. Its furthest stage is phase 1, for ewing sarcoma, hepatocellular carcinoma, biliary tract cancer and advanced solid tumours. ClinicalTrials.gov registers it in one study linked below. Phase 1/1b NCT07197554 recruiting; company milestone '1Q 2027: Phase 1a Data'. Whether it works in people has not been established unless a trial below reports it.

## Fields

- Kind: Treatment
- Status: phase-1
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Code: ST-01156
- Modality: Oral small-molecule molecular glue degrader
- Mechanism: An orally given, brain-penetrant small-molecule degrader of RBM39 that brings RBM39 together with the E3 ligase DCAF15, designed to remove oncogenic RNA-splicing dependencies across tumour types.

## Sources

- SEED Therapeutics: seedtherapeutics.com: https://seedtherapeutics.com/pipeline
- SEED Therapeutics: seedtherapeutics.com: https://seedtherapeutics.com/pipeline
- SEED Therapeutics: seedtherapeutics.com: https://seedtherapeutics.com/
- SEED Therapeutics: clinicaltrials.gov: https://clinicaltrials.gov/api/v2/studies/NCT07197554
- ClinicalTrials.gov: trials of ST-01156: https://clinicaltrials.gov/search?intr=ST-01156

## Connected records

- cancers: [Biliary tract cancer (all types)](https://onco.cc/cancers/biliary-tract-cancer/), [Ewing sarcoma](https://onco.cc/cancers/ewing-sarcoma/), [Hepatocellular carcinoma](https://onco.cc/cancers/hcc/), [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- targets: [RBM39](https://onco.cc/targets/rbm39/)
- companies: [SEED Therapeutics](https://onco.cc/companies/seed-therapeutics/)
- trials: [A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies](https://onco.cc/trials/nct07197554/)

---
JSON: https://onco.cc/api/v1/entities/st-01156.json